Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Geneva: World Health Organization
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
Visit our website, join the waitlist, and take the first step
Goldman Sachs projects $95 billion by 2030, factoring in pricing pressure, discontinuation rates, and access barriers
Week 5 8: Significant Changes Begin Tirzepatide results per week begin to show more clearly, with average losses of 1-3 pounds per week
